作者: Katsumata, Takahiro ; Fujii, Shota ; Suzuki, Akiyo ; Hanaoka, Nobuharu ; Nemoto, Shintaro ; Konishi, Hayato ; Nakamura, Koichiro ; Matsubara, Chisa ; Suzuki, Tatsuya

Abstract:

OBJECTIVES:

Air leakage after lung resection is a common morbidity that may lengthen hospital stay. Applying sealant to a lesion is an effective prophylaxis in clinical practice. This study aimed to examine the effect of a combination of a bioabsorbable polyglycolic acid (PGA) fabric and fibrin glue (FG) on air sealing by measuring the in vitro mechanical strength and degradation of the fabric, and in vivo histological changes after implantation.

METHODS:

A defect was created in the canine left upper lung lobe, and then filled with a fibrinogen solution and covered with a PGA sheet spray-coated with fibrinogen and thrombin. After 1 and 4 weeks, air leakage from the lesion was examined in vivo under airway pressure. Tissue samples were harvested for histological assessment.

RESULTS:

The mechanical strength of the PGA fabric remained at 80–90% of the baseline level for 1 week in phosphate-buffered saline, and then rapidly decreased to zero thereafter. Air leakage from the lung defect was prevented by the combination of PGA fabric and FG at 1 and 4 weeks. Histological examinations showed that PGA bundles persisted with a non-specific inflammatory response for 2 weeks and then gradually broke into sparse yarns surrounded by collagen fibres and capillaries by 8 weeks. The lung defect was filled with FG at 1 week and by granulation tissue thereafter.

CONCLUSIONS:

These results provide evidence for the efficacy of a combination of PGA fabric and FG for the prevention of air leakage in the critical period after lung surgery.

2015-01-01·SEN-I GAKKAISHI

In Vitro Evaluation of Paclitaxel‐Eluting fully Bioabsorbable Stents with PLLA Coating

作者: Yamane, Hideki ; Kinoshita, Mitsuhiko ; Matsubara, Chisa ; Igaki, Keiji ; Yamada, Hirokazu ; Yagi, Shinichi ; Yoshida, Yuji

A drug-eluting hilly bioabsorbable stent which is made of poly(L-lactic acid) (PLLA) and coated with a drug using PLLA as coating substrate was developed.Drug release behavior from the stent was evaluated in vitro in terms of different mol. weights of substrate PLLA and different coating methods.Four different types of coating method including, PLLA spray coating on the PLLA stent followed by immersion in the drug solution (type I), spray coating of PLLA/drug mixture (type 2), spray coating of PLLA/drug mixture followed by the heating process (type 3), and spray coating of PLLA/drug mixture followed by immersion in the drug solution (type 4), were employed.The inner and surface structures of the spray coated layer varied depending on the mol. weights of PLLA and/or the drug coating methods, and consequently led to the change in the amount of drug contained as well as the drug releasing behavior.Spraying a pure PLLA onto stent created a dense PLLA coating layer, which prevented the invasion of the drug deep in the layer, and the drug was just only adhered to the pure PLLA surface, resulted in the significant reduction of drug content on the stent surface.On the contrary, the spray coating of PLLA/drug mixture provided a porous layer, which allowed for the drug to invade deep into the layer and resulted in increase of drug content.Porosity and the size of the pore tended to decrease with increasing PLLA mol. weight, and drug release rate also decreased accordingly.Addnl. heat process facilitated PLLA crystallization, leading to significant reduction of the drug release rate.

2012-05-15·Circulation1区 · 医学

Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly- l -Lactic Acid Coronary Stents

1区 · 医学

Article

作者: Seki, Junya ; de Winter, Sebastiaan ; Igaki, Keiji ; Muramatsu, Takashi ; Akamatsu, Shunji ; Kosuga, Kunihiko ; Brugaletta, Salvatore ; Takeuchi, Eiji ; Takeuchi, Yuzo ; Inuzuka, Yasutaka ; Bruining, Nico ; Ikeguchi, Shigeru ; Nishio, Soji ; Takeda, Shinsaku ; Kyo, Eisho ; Onuma, Yoshinobu ; Kawada, Yoshitaka ; Serruys, Patrick W. ; Harita, Takeshi ; Hasegawa, Shinichi ; Hata, Tatsuhiko ; Okada, Masaharu ; Tsuji, Takafumi

Background—:

The purpose of this study was to evaluate the long-term safety of the Igaki-Tamai stent, the first-in-human fully biodegradable coronary stent made of poly- l -lactic acid.

Methods and Results—:

Between September 1998 and April 2000, 50 patients with 63 lesions were treated electively with 84 Igaki-Tamai stents. Overall clinical follow-up (>10 years) of major adverse cardiac events and rates of scaffold thrombosis was analyzed together with the results of angiography and intravascular ultrasound. Major adverse cardiac events included all-cause death, nonfatal myocardial infarction, and target lesion revascularization/target vessel revascularization. During the overall clinical follow-up period (121±17 months), 2 patients were lost to follow-up. There were 1 cardiac death, 6 noncardiac deaths, and 4 myocardial infarctions. Survival rates free of all-cause death, cardiac death, and major adverse cardiac events at 10 years were 87%, 98%, and 50%, respectively. The cumulative rates of target lesion revascularization (target vessel revascularization) were 16% (16%) at 1 year, 18% (22%) at 5 years, and 28% (38%) at 10 years. Two definite scaffold thromboses (1 subacute, 1 very late) were recorded. The latter case was related to a sirolimus-eluting stent, which was implanted for a lesion proximal to an Igaki-Tamai stent. From the analysis of intravascular ultrasound data, the stent struts mostly disappeared within 3 years. The external elastic membrane area and stent area did not change.

Conclusion—:

Acceptable major adverse cardiac events and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent.

项与 Kyoto Medical Planning Co., Ltd. 相关的新闻（医药）

2023-05-24

·Business Wire

Global Bioabsorbable Stents (BAS) Pipeline Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents. Scope Extensive coverage of the Bioabsorbable Stents (BAS) under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Bioabsorbable Stents (BAS) Overview 3 Products under Development 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 5 Bioabsorbable Stents (BAS) Companies and Product Overview 5.1 Abbott Vascular Inc Company Overview 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 5.2 Amaranth Medical Inc Company Overview 5.3 Arterius Ltd Company Overview 5.4 Biosensors International Group Ltd Company Overview 5.5 Biosten, LLC Company Overview 5.6 Biotronik AG Company Overview 5.7 Biotronik SE & Co KG Company Overview 5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview 5.9 Boston Scientific Corp Company Overview 5.10 Cardionovum GmbH Company Overview 5.11 Cordis Corp Company Overview 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 5.13 Icon Interventional Systems, Inc. Company Overview 5.14 Japan Stent Technology Co., Ltd. Company Overview 5.15 Kyoto Medical Planning Co Ltd Company Overview 5.16 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 5.17 Manli Cardiology Ltd Company Overview 5.18 Meril Life Sciences Pvt Ltd Company Overview 5.19 Micell Technologies Inc Company Overview 5.20 Michigan Technological University Company Overview 5.21 MicroPort Scientific Corp Company Overview 5.22 Minvasys SAS Company Overview 5.23 MIV Therapeutics Inc Company Overview 5.24 NanoCoeur, Inc. Company Overview 5.25 North Carolina State University Company Overview 5.26 Northwestern University Company Overview 5.27 OrbusNeich Company Overview 5.28 Pediastent LLC Company Overview 5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview 5.30 REVA Medical Inc Company Overview 5.31 S3V Vascular Technologies Company Overview 5.32 Shanghai Bio-heart Biological Technology Co Ltd Company Overview 5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview 5.34 Tepha Inc Company Overview 5.35 Tremedics Medical Devices LLC Company Overview 5.36 UAB Minority Health and Health Equity Research Center Company Overview 5.37 University of Florida Company Overview 5.38 University of Strathclyde Company Overview 5.39 VasoTech Inc. Company Overview 5.40 Xenogenics Corporation Company Overview 6 Bioabsorbable Stents (BAS)- Recent Developments 6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million 6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022 6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022 6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule 6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022 6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/d7bf3z About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

财报

2021-05-31

·GlobeNewswire

Bioabsorbable Stents Market to Grow at $308.9 Million by 2027

Portland, OR, May 31, 2021 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the global Bioabsorbable Stents Market was pegged at $283.6 million in 2019, and is estimated to reach $308.9 million by 2027, growing at a CAGR of 5.6% from 2020 to 2027. Rise in prevalence of heart diseases coupled with increase in geriatric population, surge in technological advancements in bioabsorbable stents, and rise in demand for the minimally invasive procedure have boosted the growth of the global bioabsorbable stents market. Moreover, growth in development of healthcare infrastructure and rise in R&D supplemented the market growth. However, high cost and risk of procedure associated with bioabsorbable stents hinder the market growth. On the contrary, surge in R&D and advancements in technology is expected to create lucrative opportunities for the market players in the future. Download Sample Report at: Covid-19 scenario: The global bioabsorbable stents market is segmented on the basis of biomaterial, application, end user, and region. Based on biomaterial, the polymeric stents segment held the lion’s share in 2019, contributing to nearly three-fifths of the market. However, the metallic stents segment is estimated to register the highest CAGR of 6.3% from 2020 to 2027. On the basis of application, the coronary artery disease segment dominated the market in 2019, accounting for nearly three-fourths of the market. Moreover, the segment is expected to portray the highest CAGR of 6.3% during the forecast period. Enquiry for Short-term and Long-term Impacts of COVID-19 at: The global bioabsorbable stents market is analyzed across several regions such as North America, Europe, Asia-Pacific, and LAMEA. The market across North America held the largest share in 2019, accounting for more than two-fifths of the market. However, the market across Asia-Pacific is projected to manifest the highest CAGR of 6.3% during the forecast period. The global bioabsorbable stents market includes an in-depth analysis of the prime market players such as Arterius Limited, Arterial Remodeling Technologies, Biotronik SE & Co. KG, B. Braun Melsungen AG, the Elixir Medical Corporation, Boston Scientific Corporation, Kyoto Medical Planning Co. Ltd., Microport Scientific Corporation, Terumo Corporation, and Reva Medical. Avenue Basic Plan | Library Access | 1 Year Subscription | Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan. Avenue Library Subscription | Request for 14 days free trial of before buying: Get more information: We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Similar Reports: Stents Market - Global Opportunity Analysis and Industry Forecast, 2020–2027 Cardiac Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2019-2027 Vascular Guidewires Market - Global Opportunity Analysis and Industry Forecast, 2019-2027 Heart Blocks Treatment Market - Global Opportunity Analysis and Industry Forecast, 2019–2027 Coronary Stents Market - Global Opportunity Analysis and Industry Forecast, 2019–2027 Pancreatic Stents Market - Global Opportunity Analysis and Industry Forecast, 2019–2027 Radioactive Stents Market - Global Opportunity Analysis and Industry Forecast, 2019–2027 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

100 项与 Kyoto Medical Planning Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Kyoto Medical Planning Co., Ltd. 相关的转化医学

登录后查看更多信息